

**Natco Pharma Limited** 

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

July 4, 2022

Corporate Relationship Department M/s. BSE Ltd Dalal Street, Fort Mumbai- 400 001 Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) Mumbai -400 051

Scrip Code: 524816 Dear Sir, Scrip Code: NATCOPHARM

Please find enclosed herewith Certificate under Regulation 74(5) of the SEPI (Depositories and Participants) Regulations for the quarter ended June 30, 2022.

Kindly acknowledge receipt of the same.

Thanking you

Yours faithfully For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary Compliance Officer

Encl. As Above.



Date: 04.07.2022

To, The Company Secretary, Natco Pharma Limited, Natco House, Road No.2, Banjara Hills, Hyderabad – 500 034

Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.2022

Ref: Security Code - 524816ISIN : INE987B01026

Dear Sir/Madam,

We hereby certify that the securities received for dematerialisation have been mutilated and cancelled after due verification and the name of the depositories (National Securities **Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL)** has been updated in the records of company as the registered owner within 15 days of receipt of valid DRF & Share certificate of said company and the details of securities are furnished to the stock exchange(s).

We request you to take this information on record and to inform Depositories(s) and Stock Exchange(s) wherever your securities are listed accordingly.

Thanking you,

Yours faithfully,

For Venture Capital and Corporate Investments Private Limited.

Q

Authorised Signatory.